H.R. 4053 · 118th Congress (2023–2025)
Studying Suboxone Act
This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)
Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes.
!--tinycomments|2.1|data:application/json;base64,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-->Show official title
To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.
Expired in House committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to Health
This bill’s path
This is H.R. 4053’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Ann M. Kuster (D-NH-2)
- Cosponsors
3 cosponsors
1 original · 2 later
- Rep. Earl L. "Buddy" Carter (R-GA-1)· Original · Jun 13, 2023
- Rep. Paul Tonko (D-NY-20)· Later · Jun 20, 2023
- Rep. Marcus J. Molinaro (R-NY-19)· Later · Jan 3, 2024
- Policy area
- Health
- Subjects
- Drug trafficking and controlled substances
- Government studies and investigations
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
▸ 2 committee actions · Jun 13, 2023 – Jun 16, 2023
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Expired
Introduced → Referred to House Health → No further action before the 118th Congress ended.
Committees
Jun 21, 2023 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
Studying Suboxone Act
Display title, Short title · Introduced in House
To provide for the review of the scheduling under the Controlled Substances Act of buprenorphine-naloxone combination products, and for other purposes.
Official title · Introduced in House